Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
Date:5/1/2008

Company to Provide Financial Guidance for Fiscal 2008 through 2010

PITTSBURGH, May 1 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Thursday, May 8, 2008, at 5 p.m. ET to provide a review of the first quarter ended March 31, 2008. The company also will provide updated financial guidance for fiscal 2008 through fiscal 2010 and an operational and integration update on Merck Generics, which the company acquired on Oct. 2, 2007. The company will release its financial results after the market closes May 8.

The dial-in number to access the May 8 call is 877-719-9810 or 719-325-4793 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 4576196.

To access a live webcast of the May 8 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest-and highest quality-product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information abou
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
3. Mylan Announces Final FDA Approval for Trandolapril Tablets
4. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
5. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
6. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
7. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
8. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
9. Mylan Restores Availability of Generic Levothyroxine in Florida
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... of The Royal Marsden Hospital Manual of Clinical Nursing ... format that organises 15 key chapters into four key ... on areas such as risk management and preparing patients ... from the world-renowned UK centre of excellence, the Manual ...
... HealthDay Reporter , SUNDAY, April 3 (HealthDay News) -- Diabetes ... suggests an increased risk of cancer can be added to that ... had an 8 percent increased risk of developing cancer generally, while ... of prostate cancer were excluded from the calculation. The risk ...
... 4 (HealthDay News) -- Taking aspirin even once per month, ... a marked drop in the risk of developing pancreatic cancer, ... was linked to a 26 percent reduction in the risk ... of heart disease, was associated with an even greater drop ...
... be assessed by examining the epithelial cells found in ... the AACR 102nd Annual Meeting 2011, held April 2-6. ... provide a personalized assessment of breast cancer risk, said ... veterinary and animal sciences at the University of Massachusetts ...
... Prostate cancer is the second leading cause of cancer-related death ... reduced the number of deaths from the disease. By ... risk for aggressive disease or diagnosis at a young age, ... screening approach. For that reason, scientists have been looking for ...
... (March 29, 2011) Medicare coverage and nationwide ... as virtual colonoscopy, has tripled in recent years, according ... Journal of the American College of Radiology ... produce a three-dimensional visualization that permits a thorough and ...
Cached Medicine News:Health News:Patient's journey format drives new edition of vital student nurse manual 2Health News:Patient's journey format drives new edition of vital student nurse manual 3Health News:Add Cancer to Health Risks of Diabetes: Study 2Health News:Add Cancer to Health Risks of Diabetes: Study 3Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 2Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 3Health News:Breast milk may provide a personalized screen of breast cancer risk 2Health News:MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men 2Health News:Nationwide utilization of virtual colonoscopy triples, study suggests 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dornier Compact Delta lithotripsy system features real value ... systems shock source and C-arm are fully integrated ... risk of misalignment. The therapy head on the ... lateral and horizontal movement and can treat in ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: